Tesamorelin side effects.

Tesamorelin side effects

Injection-site redness or itching, aching joints, muscle pain and swelling are the main practical side effects. Tingling, numbness and rash also occurred in the original EGRIFTA trials. Blood sugar and IGF-1 need separate attention because an abnormal result may not produce an obvious sensation. [1]

Original EGRIFTA trials in adults with HIV-associated lipodystrophy: 543 treated and 263 placebo participants over 26 weeks. Injection reactions use the label's overall 25%/14% category; the other figures are individual adverse-event rows. These rates were not measured for the supplied research vial or pen. [1]

Blood sugar and diabetes

HbA1c reached at least 6.5% in 5% of tesamorelin participants versus 1% with placebo over 26 weeks. The label reports an increased diabetes risk, with a hazard ratio of 3.3. That is a real monitoring issue even though average blood-sugar results can look stable across a whole study. [1]

Check glucose status before prescribed treatment and repeat testing during it. Existing diabetes may require closer monitoring and changes to diabetes medication by the treating clinician. The label also calls for attention to diabetic retinopathy because IGF-1 rises. Diabetes is not listed as an automatic contraindication, but uncontrolled glucose changes the risk discussion. [1]

Raised IGF-1

36% of participants had IGF-1 more than three standard deviations above the reference level at week 26. IGF-1 is part of the growth-hormone response, but a larger rise is not a validated target for better fat loss. Long-term effects of persistent high levels remain uncertain. [1]

Blood-test interpretation and treatment review, not a self-directed dose-adjustment formula. The label does not prescribe one testing interval for every patient. [1]

Swelling, aching joints and numb hands

Tesamorelin can cause fluid retention through its effect on growth-hormone release. This can make rings or shoes feel tighter and can accompany joint discomfort. Hand or wrist tingling, numbness or pain can indicate carpal tunnel symptoms; that event occurred in 1% of treated participants versus none on placebo. [1]

Contact the prescribing clinician for new swelling, worsening joint pain or hand/wrist symptoms. The label describes these effects as sometimes transient or resolving after discontinuation, but it does not give a guaranteed number of days. Do not add a diuretic or another peptide to mask unexplained swelling.

Fluid-related scale changes can occur alongside changes in body composition. Tesamorelin's approved use targets excess abdominal visceral fat; an increase or decrease in total body weight alone does not identify the cause of swelling. [1] Visceral fat, body weight and lean mass →

Injection reactions, infection and allergy

Hypersensitivity reactions occurred in 4% of EGRIFTA trial participants. That category included itching, flushing, redness, hives and rash; it is not a 4% anaphylaxis rate. The supplied pen also contains 0.9% benzyl alcohol, so a reaction cannot automatically be assigned to the peptide alone. [1] [3]

Cancer, pituitary conditions and pregnancy

Active cancer is a contraindication to EGRIFTA. Tesamorelin raises growth hormone and IGF-1, so a history of cancer requires a specific benefit–risk review after the malignancy is inactive and treatment is complete. The available data do not establish a general cancer-risk percentage for healthy fitness users. [1]

FDA contraindications for EGRIFTA. A prior minor head injury alone is not enough to diagnose disrupted pituitary function. [1]

Women are not given a separate lower dose in the label. Pregnancy and breastfeeding are different questions from dose size; use during pregnancy is contraindicated, and the patient information advises against breastfeeding during treatment. Evidence in children, adults older than 65 and people with kidney or liver impairment is limited or missing. [1]

Tesamorelin with other medicines and peptides

Adding HGH, ipamorelin or CJC-1295 creates a different hormone regimen. Their use together is not an EGRIFTA-approved protocol. The tesamorelin trial results cannot supply a safe combined amount or prove extra fat loss from such a stack.

Glucocorticoid replacement deserves particular attention. Growth-hormone stimulation can change cortisone-to-cortisol conversion, and maintenance or stress dosing may need adjustment by the clinician. The label also recommends monitoring combinations with medicines whose clearance can change through liver enzymes, including some sex steroids, anticonvulsants and cyclosporine. [1]

A GLP-1 medicine such as tirzepatide or semaglutide does not remove the need to monitor glucose during tesamorelin treatment. Supply the complete medication list for a clinical review; independently changing diabetes drugs or steroids to offset a new effect can create a second problem.

Product quality and storage

No batch-specific certificate is available for the supplied Tesamorelin products. There is no verified lot-specific purity, content, endotoxin or sterility result to display. A product safety sheet does not supply those laboratory results. Product testing and certificate status →

The pen holds 10 mg in 3 mL; prepared vial material and the pen require 2–8°C (36–46°F), protected from light. Do not freeze the pen. Sealed powder has separate −20°C (−4°F) storage instructions, and neither research format has a supplied in-use lifespan. EGRIFTA's own handling rules differ. [3] WR and SV preparation and storage →

Preservatives do not make poor handling harmless. CDC recommends fresh sterile injection equipment and discarding a medication vial when sterility is compromised or questionable. Clear liquid and refrigeration cannot verify sterility. [5]

Tesamorelin and drug-tested sport

Tesamorelin is prohibited at all times under the 2026 WADA list. It appears in S2.2.4 among growth-hormone-releasing factors. The restriction applies in and out of competition. A prescription or an ordinary workplace drug-screen result does not by itself establish eligibility for a tested sport. [6]